No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer.
BACKGROUND
Increased insulin-like growth factor (IGF)-I and IGF-II concentrations are related to increased colorectal cancer risk. Isoflavones have been associated with reduced colorectal cancer risk, and may affect the IGF system because of their weak estrogenic activity. The aim of the study was to investigate the effect of isolated isoflavones on serum concentrations of IGF system components.


METHODS
We conducted a randomized, placebo-controlled, double-blinded, crossover trial in four hospitals in the Netherlands to investigate the effect of an 8-week supplementation with red clover-derived isoflavones (84 mg/d) on serum IGF-I concentrations. In addition, serum concentrations of IGF-II and IGF binding proteins (IGFBP)-1, IGFBP-2, and IGFBP-3 were assessed. Normal colorectal tissue biopsies were obtained after the first intervention period and mRNA expression of IGF-I, IGF-II, IGFBP-3, and IGF-IR was evaluated. Our study population consisted of 34 postmenopausal women with a family history of colorectal cancer or a personal history of colorectal adenomas.


RESULTS
Isoflavone supplementation did not significantly affect serum concentrations of total IGF-I (mean relative within-person difference; IGF-I, -2.0%; 95% confidence interval, -8.0% to 3.9%). IGF-II and IGFBPs were also not significantly altered after isoflavone supplementation. Colorectal tissue mRNA expression of IGF system components did not significantly differ between individuals on isoflavone supplementation and those who received placebo.


CONCLUSIONS
The results of our trial, supported by a qualitative review of soy trials published to date, suggest that isoflavones do not significantly affect circulating levels of IGF system components. Increased levels of IGF-I, as observed in most of these trials, are likely due to simultaneous protein supplementation.
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Alina
A
Vrieling
Matti A
MA
Rookus
Ellen
E
Kampman
Johannes M G
JM
Bonfrer
Astrid
A
Bosma
Annemieke
A
Cats
Jaap
J
van Doorn
Catharina M
CM
Korse
Ben J M
BJ
Witteman
Flora E
FE
van Leeuwen
Laura J
LJ
van't Veer
Dorien W
DW
Voskuil
D000368:Aged; D015179:Colorectal Neoplasms / Q000097:blood*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D007529:Isoflavones / Q000494:pharmacology*; D008875:Middle Aged; D010919:Placebos; D029921:Trifolium
D018969:Insulin-Like Growth Factor Binding Proteins; D007529:Isoflavones; D010919:Placebos; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II